Asieris publishes Annual Report and shares Market approval of Richard Wolf System blue equipment in China

Oslo, Norway, April 17, 2026: Photocure’s partner Asieris today communicated publication of their 2025 annual report in a media release. Beyond progress with Cevira^® and Hexvix^®, in this release, Asieris share that Richard Wolf’s System blue equipment has been approved for the Chinese market this month: 

“In urologic oncology, Hexvix^®, China’s first approved blue-light imaging agent for bladder cancer, has opened a new era of blue-light diagnosis and treatment for bladder cancer in the country. The SYSTEM BLUE blue-light cystoscopy system, developed by Asieris’ partner R.WOLF, received market approval in April 2026 and is expected to work in synergy with Hexvix to benefit patients. In parallel, Asieris is advancing the global development of a single-use flexible blue-light cystoscope. The product has been submitted for registration in the European Union and has been formally accepted for review.”

Read Asieris’ full media release here: https://asieris.com/asieris-pharmaceuticals-releases-2025-annual-report%ef%bc%9aflagship-product-approval-marks-inflection-point-commercialization-2-0-drives-growth/